The objective of this research was to investigate the mechanism by which human tumor–derived TGF-β suppresses the immune function of human CD4+ T cells. This research was performed with biological material (tumor effusions and T cells) from patients with cancer, as well as T cells isolated from the peripheral blood of healthy donors. The experimental design consisted of controlled laboratory in vitro studies and ex vivo analyses of patient cells as described. No data were excluded from the analyses. Experiments were performed at least three times using cells from independent human donors. Exact numbers of replicates are stated in the figure legends.

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.